IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice (PRESTO)
IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan
Sponsor: Abbott
Listed as NCT02115269, this observational or N/A phase trial focuses on Headache Disorders, Primary and Migraine With Aura and remains completed. Sponsored by Abbott, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 2 earlier versions
-
Oct 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Oct 2017 [monthly]
Completed NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Almedis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aktobe, Kazakhstan , Almaty, Kazakhstan , Astana, Kazakhstan , Dnipropetrovsk, Ukraine , Karaganda, Kazakhstan , Kharkiv, Ukraine , Kiev, Ukraine , Kostanay, Kazakhstan , Kyiv, Ukraine , Lutsk, Ukraine and 8 more locations